Drug coated balloon and preparation method thereof
A drug coated balloon includes a balloon body and a drug loaded coating layer. The drug loaded coating layer includes a first drug loaded coating component having at least two controllable sustained release drugs with different drug release kinetics, and a second drug loaded coating component including an active drug. The second drug loaded coating component is dispersed among the controllable sustained release drugs and couples the controllable sustained release drugs on the balloon body. The first and second drug loaded coating components are both non-hydrophilic compositions. The drug coated balloon provides sufficient initial drug loading dosage to the lesion site, and has adjustable drug release rate, thereby allowing the drug coated balloon to provide bioactive drugs to the treatment site at different stages of the cascade reaction of vascular restenosis, providing the controllable long-acting therapeutic drugs, and improving the overall vascular drug release efficacy.
1. A drug coated balloon, comprising a balloon body and a drug loaded coating layer coated on an outer surface of the balloon body,
wherein the drug loaded coating layer comprises:
a first drug loaded coating component comprising at least two controllable sustained release drugs with different drug release kinetics; and
a second drug loaded coating component comprising an active drug in a free unbound form, dispersed among different controllable sustained release drugs in the first drug loaded coating component and coupling the controllable sustained release drugs onto the balloon body,
wherein both the first drug loaded coating component and the second drug loaded coating component are non-hydrophilic compositions,
wherein the active drug in a free unbound form directly couples the controllable sustained release drugs onto the balloon body, without any additional binding matrix, and
wherein the active drug in a free unbound form is attached to the balloon body in a form of separated drug particles, rather than in a form of drug membranes.
2. The drug coated balloon according to claim 1 , wherein the active drug in a free unbound form is processed by dissolving a pure drug of the active drug in a dispersion liquid or adding a particle form of the active drug to the dispersion liquid.
3. The drug coated balloon according to claim 2 , wherein the dispersion liquid comprises at least one of methanol, ethanol, isopropanol, n-hexane, heptane, petroleum ether, water, ethyl acetate, and acetone.
4. The drug coated balloon according to claim 1 , wherein each of the controllable sustained release drugs is encapsulated in a polymer as a carrier to form drug loaded particles, and the polymer is biocompatible and bioabsorbable.
5. The drug coated balloon according to claim 4 , wherein the polymer is selected from at least one of polylactic acid, polyglycolic acid, a copolymer of lactic acid and glycolic acid, and polydioxanone.
6. The drug coated balloon according to claim 4 , wherein the different drug release kinetics of the controllable sustained release drugs is regulated at least by: using different types of polymers, using different molecular weights of polymers, controlling different ratio of polymer to drug, or controlling different ratio of surface area to volume of the drug loaded particles.
7. The drug coated balloon according to claim 4 , wherein the first drug loaded coating component comprises a first controllable sustained release drug and a second controllable sustained release drug, a drug loading of the first controllable sustained release drug is not less than 30% by weight, and a drug loading of the second controllable sustained release drug is less than 30% by weight.
8. The drug coated balloon according to claim 7 , wherein the drug loading of the first controllable sustained release drug is 30-45% by weight, and the drug loading of the second controllable sustained release drug is 10-20% by weight.
9. The drug coated balloon according to claim 7 , wherein by weight percentage, the drug loaded coating layer is constituted by 10%-30% from the first controllable sustained release drug, 20%-50% from the second controllable sustained release drug, and 20%-50% from the active drug in a free unbound form.
10. The drug coated balloon according to claim 1 , wherein the first drug loaded coating component comprises at least two controllable sustained release sirolimus, and the second drug loaded coating component comprises sirolimus in a free unbound form.